Vor Biopharma Inc. (VOR)
After hours:
- Zacks
Why You Shouldn't Bet Against Vor Biopharma (VOR) Stock
Vor Biopharma (VOR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- Simply Wall St.
Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
- GlobeNewswire
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
Trem-cel and VCAR33ALLO clinical trial data expected in the second half of 2024VCAR33ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends into second half of 2025 CAMBRIDGE, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2023, and provided a business update. “We are very pleased w
